title: Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
abstract: OBJECTIVE
  To compare the efficacy and tolerability of a 3-day quadruple therapy with a standard 7-day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers.
  
  
  METHODS
  Patients with H. pylori-positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM-7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB-3). No pre- or post-treatment acid suppression was used. Follow-up endoscopy was performed at week 6.
  
  
  RESULTS
  A total of 118 patients were recruited. Sixty patients in the LCM-7 group and 53 patients in the LCMB-3 group returned for endoscopy. Intention-to-treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM-7 and LCMB-3 groups, respectively. Per protocol and intention-to-treat ulcer healing rates were 98% and 98% in LCM-7 and 100% and 91% in LCMB-3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side-effects was found in the LCMB-3 group.
  
  
  CONCLUSIONS
  The 3-day quadruple therapy is highly effective, better tolerated and can be considered as a first-line therapy in duodenal ulcer management.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. bcywong@hku.hk
authors.forename: B C
authors.initials: BC
authors.lastname: Wong
authors.forename: W H
authors.initials: WH
authors.lastname: Wang
authors.forename: W M
authors.initials: WM
authors.lastname: Wong
authors.forename: G K
authors.initials: GK
authors.lastname: Lau
authors.forename: F M
authors.initials: FM
authors.lastname: Fung
authors.forename: N N
authors.initials: NN
authors.lastname: Kung
authors.forename: K M
authors.initials: KM
authors.lastname: Chu
authors.forename: K C
authors.initials: KC
authors.lastname: Lai
authors.forename: W H
authors.initials: WH
authors.lastname: Hu
authors.forename: F L
authors.initials: FL
authors.lastname: Hu
authors.forename: X G
authors.initials: XG
authors.lastname: Liu
authors.forename: C K
authors.initials: CK
authors.lastname: Chan
authors.forename: M F
authors.initials: MF
authors.lastname: Yuen
authors.forename: W M
authors.initials: WM
authors.lastname: Hui
authors.forename: S K
authors.initials: SK
authors.lastname: Lam
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000863:Antacids / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009942:Organometallic Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000863:Antacids; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D009942:Organometallic Compounds; D064747:Lansoprazole; D008795:Metronidazole; D017291:Clarithromycin; C002791:bismuth tripotassium dicitrate; D009853:Omeprazole